ASHPOfficial

Hospitals that are looking for alternate ways to provide acute-level care to select patients can consider the Hospital at Home program where patients can be safely monitored and managed from their home. This podcast will review the benefits, challenges, and technologies that have been used by organizations that have successfully implemented this service. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Learn from experts in the field on treatment and management of C diff infection. Topics will include treatment plans and management strategies for our patients.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Specialty pharmacy is a rapidly growing practice area within pharmacy, and has many unique career opportunities for students and new practitioners. In this episode, pharmacy students who currently work at health system specialty pharmacies discuss their roles and experiences in specialty pharmacy.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In this featurette from the 2021 Midyear Clinical Meeting, our content matter experts compare the toxicities of immunotherapy versus chemotherapy and the timeline for these toxicities to the skin, gastrointestinal, hepatic, renal, pulmonary and endocrine systems and recommend appropriate follow-up for patients with immune-related adverse effects from endocrine systems. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In this fun, informative, debate-style presentation from the 2021 Midyear Clinical Meeting, our content matter experts debate the use of gabapentin as an agent for pain in opioid-sparing multimodal pain regimens or is it a wolf in sheep’s clothing?

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

The aim of this podcast is to share the experiences and insights of two pharmacists who have transitioned between clinical practice and academia during their careers. Listeners will gain perspective on the roles/responsibilities associated with clinical versus academic positions, benefits and challenges of each, and factors that contributed to the transitions in the speakers' practice journeys. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Hospitals that are looking for alternate ways to provide acute-level care to select patients can consider the Hospital at Home program where patients can be safely monitored and managed from their home.  This podcast will review the benefits, challenges, and technologies that have been used by organizations that have successfully implemented this service. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This podcast will review the current guidelines and summarize recent literature evaluating the use of aspirin for primary prevention. Additionally, the speakers will discuss how to talk with patients about the use of aspirin in primary prevention and when to desprescribe vs. continue therapy.  

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Tom and Jillanne will discuss recent developments in manufacturer efforts to undercut the 340B program, as well as the recent Supreme Court ruling that requires CMS refund 340B underpayments to hospitals. We’ll cover ASHP’s advocacy strategy and touch on how covered entities can protect themselves in the current climate.  

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Monkeypox was first detected in the United States in May and earlier in August, the Department of Health and Human Services (HHS) declared monkeypox a public health emergency (PHE), signaling increased urgency as the Biden administration broadens the push to contain the virus. The World Health Organization (WHO) declared monkeypox a global health emergency on July 23, and health officials in many states, including New York, California, and Illinois, have made similar declarations. This podcast will highlight what you need to know for yourself, your community, and your patients.  

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.